glp 1 and gip function Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research Glucagon-like peptide-1 - Wikipedia

Una meta-analisi su soggetti in sovrappeso/obesi non diabetici (International Journal of Obesity, 2025), che ha analizzato gli eventi GI con un modello network dose-risposta, ha confermato che il rischio dose-dipendente e pi pronunciato nella fase di titolazione

Your medication ships directly to your door

While individual results can vary, the average weight loss is 1 to 3 pounds per week

continued treatment helps maintain losses Common side effects that may affect treatment adherence include: Nausea and vomiting (usually temporary, improving after several weeks) Diarrhoea or constipation Abdominal discomfort Fatigue Injection site reactions Important safety considerations include: Risk of hypoglycaemia if used with insulin or sulfonylureas [4] Do not stop or reduce insulin rapidly without medical advice (risk of diabetic ketoacidosis) [4] Maintain adequate hydration to prevent acute kidney injury [4] Potential for gallbladder problems (pain, stones) Rare risk of intestinal obstruction Possible worsening of diabetic retinopathy in people with diabetes during rapid improvement in blood glucose For tirzepatide: use additional non-oral contraception for 4 weeks after initiation and each dose escalation Patients should contact their GP if they experience: persistent vomiting preventing fluid intake, severe abdominal pain, signs of gallbladder disease, or unusual thyroid symptoms

RCT supports the rare occurrence of thyroid cancer diagnosis during relatively short follow-up periods, and without conclusive evidence of increased risk of thyroid cancer in GLP-1 RA users

Brain Access The profound impact of GLP-1 and its analogs on the human brain activity is unquestionable (137-139)